`Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare'. Nature Biotechnology, Vol.21, pp.747-753.Shah J. Economic and regulatory considerations in pharmacoge- nomics for drug licensing and healthcare. Nature Biotechnology 2003;21(7):747-753...
Shah J. Economic and regulatory considerations in pharmacoge- nomics for drug licensing and healthcare. Nature Biotechnology 2003;21(7):747-753Shah J. Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare. Nat Biotechnol 2003; 21(7): 747-53....
Elective, office-based surgery has captured the interest of consumers and, more recently, the attention of state health care regulatory agencies. In most s... MS Quattrone - 《Journal of Ambulatory Care Management》 被引量: 72发表: 2000年 Regulatory considerations in the establishment and expansio...
Twice each month, PYA experts discuss the latest industry developments as part of our popular Healthcare Regulatory Roundup (HCRR) webinar series. In addition to straightforward explanations of those developments and actionable guidance, attendees will be offered the chance to earn continuing ...
Health Care Regulatory In a constantly changing health care regulatory environment, health care providers, vendors, service providers, and investors need a team that will put them in their best position to take advantage of regulatory opportunities and avoid or successfully defend regulatory violations....
“The use of judgment in ratemaking is universally recognized and accepted by regulators and falls within the scope of the actuarial standards of practice,” he said. Hartwig contends that PO is consistent with actuarial principles, which recognize that business considerations are part of ratemaking ...
healthcare IT organizations. Key Considerations When Looking for an iPaaS Provider When considering an iPaaS provider, look for these top-level capabilities: Full support for any combination of integration: cloud to cloud, cloud to on-premises, on-premises to on-premises, and EDI....
The healthcare industry in general and the pharmaceutical industry in particular are advancing at a rapid pace. As the world continues to advance, patients and families are becoming more aware of the customisation options available to them (Klein GT, Lu Y, Wang MY, World Neurosurg 80:233–235...
e change in medicines and healthcare products regulatory agency guidance for management of paracetamol poisoning an analysis of hospital admissions for paracetamol overdose in england and scotland Regulatory Considerations for Peptide Drug Products:多肽药物产品监管的思考 黄芪保健产品开发 保健产品定位报告 保健...
National Health Commission (NHC); National Healthcare Security Administration (NHSA); National Joint Drug Procurement Office; Chinese Pharmacopoeia (ChP) Commission. China‘s 7th Volume-based Procurement Includes 327 Drug Products On July 18, China National Joint Drug Procurement Office ...